Key result
New rotavirus vaccine candidates, including a bovine-human reassortant and an attenuated human monovalent vaccine, are entering Phase III trials following the withdrawal of the first licensed vaccine.
This review highlights the ongoing development of new rotavirus vaccines following the withdrawal of the first licensed vaccine due to safety concerns.
Caution advised until Phase III data emerge; extends rotavirus vaccine pipeline but leaves open clinical viability.
Rotavirus vaccines offer the best hope to reduce the toll of acute rotaviral gastroenteritis in both developed and developing countries. An association with intussusception (IS) led to the withdrawal of the first licensed rotavirus vaccine in the USA in 1999, forcing a re-evaluation of the safety profile of potentially lifesaving vaccines. Development of new rotavirus vaccine candidates has continued, with a bovine-human reassortant vaccine and an attenuated human monovalent vaccine commencing Phase III trials. Several other candidates are in early Phase I and II clinical trials. The creation of innovative funding strategies to support vaccine development and production, specifically in developing countries, aim to make vaccines available where rotavirus causes the greatest impact.
No takes yet. Share an insight, caveat, or question.
Kirkwood et al. (2003) conducted a review in acute rotaviral gastroenteritis. Rotavirus vaccines was evaluated. New rotavirus vaccine candidates, including a bovine-human reassortant and an attenuated human monovalent vaccine, are entering Phase III trials following the withdrawal of the first licensed vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: